Search Results - "Maughan, Tim"

Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies by Venderbosch, Sabine, Nagtegaal, Iris D, Maughan, Tim S, Smith, Christopher G, Cheadle, Jeremy P, Fisher, David, Kaplan, Richard, Quirke, Philip, Seymour, Matthew T, Richman, Susan D, Meijer, Gerrit A, Ylstra, Bauke, Heideman, Danielle A M, de Haan, Anton F J, Punt, Cornelis J A, Koopman, Miriam

“…To determine the prevalence and prognostic value of mismatch repair (MMR) status and its relation to BRAF mutation (BRAF(MT)) status in metastatic colorectal…”
Get full text

The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors by van Bijsterveldt, Linda, Durley, Samuel C, Maughan, Tim S, Humphrey, Timothy C

“…Preclinical models of cancer have demonstrated enhanced efficacy of cell-cycle checkpoint kinase inhibitors when used in combination with genotoxic agents…”
Get full text

Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study by Grenader, Tal, Nash, Stephen, Adams, Richard, Kaplan, Richard, Fisher, David, Maughan, Tim, Bridgewater, John

“…Background: The phase III COntinuous or INtermittent (COIN) trial failed to show non-inferiority of intermittent compared with continuous chemotherapy for…”
Get full text

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial by Crosby, Thomas, FRCR, Hurt, Christopher N, MSc, Falk, Stephen, MD, Gollins, Simon, FRCR, Mukherjee, Somnath, FRCP, Staffurth, John, MD, Ray, Ruby, PhD, Bashir, Nadim, BSc, Bridgewater, John A, FRCP, Geh, J Ian, FRCP, Cunningham, David, Prof, Blazeby, Jane, Prof, Roy, Rajarshi, FRCR, Maughan, Tim, Prof, Griffiths, Gareth, MSc

“…Summary Background Definitive chemoradiotherapy (CRT) is an alternative to surgery for the curative treatment of oesophageal carcinoma. The SCOPE1 trial aimed…”
Get full text

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial by Primrose, John, Prof, Falk, Stephen, MD, Finch-Jones, Meg, MD, Valle, Juan, Prof, O'Reilly, Derek, FRCS, Siriwardena, Ajith, Prof, Hornbuckle, Joanne, MD, Peterson, Mark, FRCS, Rees, Myrddin, MS, Iveson, Tim, MD, Hickish, Tamas, MD, Butler, Rachel, FRCPath, Stanton, Louise, MSc, Dixon, Elizabeth, MSc, Little, Louisa, RN, Bowers, Megan, MSc, Pugh, Siân, MRCS, Garden, O James, Prof, Cunningham, David, Prof, Maughan, Tim, Prof, Bridgewater, John, PhD

“…Summary Background Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with…”
Get full text

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial by Mukherjee, Somnath, Dr, Hurt, Christopher N, MSc, Bridgewater, John, MD, Falk, Stephen, MD, Cummins, Sebastian, MRCP, Wasan, Harpreet, FRCR, Crosby, Tom, FRCR, Jephcott, Catherine, FRCR, Roy, Rajarshi, FRCR, Radhakrishna, Ganesh, FRCR, McDonald, Alec, MD, Ray, Ruby, PhD, Joseph, George, MBBS, Staffurth, John, MD, Abrams, Ross A, Prof, Griffiths, Gareth, MSc, Maughan, Tim, Prof

“…Summary Background In the UK, chemotherapy is the standard treatment for inoperable, locally advanced, non-metastatic pancreatic cancer. Chemoradiotherapy is…”
Get full text

Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia by Craig, Stephanie G., Humphries, Matthew P., Alderdice, Matthew, Bingham, Victoria, Richman, Susan D., Loughrey, Maurice B., Coleman, Helen G., Viratham-Pulsawatdi, Amelie, McCombe, Kris, Murray, Graeme I., Blake, Andrew, Domingo, Enric, Robineau, James, Brown, Louise, Fisher, David, Seymour, Matthew T., Quirke, Phil, Bankhead, Peter, McQuaid, Stephen, Lawler, Mark, McArt, Darragh G., Maughan, Tim S., James, Jacqueline A., Salto-Tellez, Manuel

“…Background Immunohistochemical quantification of the immune response is prognostic for colorectal cancer (CRC). Here, we evaluate the suitability of…”
Get full text

FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing by Richman, Susan D, Hemmings, Gemma, Roberts, Helen, Gallop, Niall, Dodds, Rachel, Wilkinson, Lyndsay, Davis, Jonathan, White, Rhian, Yates, Emma, Jasani, Bharat, Brown, Louise, Maughan, Tim S, Butler, Rachel, Quirke, Philip, Adams, Richard

“…FOCUS4 was a phase II/III umbrella trial, recruiting patients with advanced or metastatic colorectal cancer, between 2014 and 2020. Molecular profiling of…”
Get more information

New role of fat-free mass in cancer risk linked with genetic predisposition by Harris, Benjamin H. L., Di Giovannantonio, Matteo, Zhang, Ping, Harris, David A., Lord, Simon R., Allen, Naomi E., Maughan, Tim S., Bryant, Richard J., Harris, Adrian L., Bond, Gareth L., Buffa, Francesca M.

“…Cancer risk is associated with the widely debated measure body mass index (BMI). Fat mass and fat-free mass measurements from bioelectrical impedance may…”
Get full text

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol by Brown, Nicholas F, Ng, Stasya M, Brooks, Claire, Coutts, Tim, Holmes, Jane, Roberts, Corran, Elhussein, Leena, Hoskin, Peter, Maughan, Tim, Blagden, Sarah, Mulholland, Paul

“…Median survival for patients with glioblastoma is less than a year. Standard treatment consists of surgical debulking if feasible followed by temozolomide…”
Get full text

Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification by Dunne, Philip D., Alderdice, Matthew, O'Reilly, Paul G., Roddy, Aideen C., McCorry, Amy M. B., Richman, Susan, Maughan, Tim, McDade, Simon S., Johnston, Patrick G., Longley, Daniel B., Kay, Elaine, McArt, Darragh G., Lawler, Mark

“…Stromal-derived intratumoural heterogeneity (ITH) has been shown to undermine molecular stratification of patients into appropriate prognostic/predictive…”
Get full text

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial by Mukherjee, Somnath, Qi, Cathy, Shaw, Rachel, Jones, Christopher M., Bridgewater, John A., Radhakrishna, Ganesh, Patel, Neel, Holmes, Jane, Virdee, Pradeep S., Tranter, Bethan, Parsons, Philip, Falk, Stephen, Wasan, Harpreet S., Ajithkumar, Thankamma V., Holyoake, Daniel, Roy, Rajarshi, Scott-Brown, Martin, Hurt, Christopher N., O’Neill, Eric, Sebag-Montefiore, David, Maughan, Tim S., Hawkins, Maria A., Corrie, Pippa

“…The multi-centre two-stage SCALOP-2 trial (ISRCTN50083238) assessed whether dose escalation of consolidative chemoradiotherapy (CRT) or concurrent…”
Get full text

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial by Wasan, Harpreet, MD, Meade, Angela M, Dr, Adams, Richard, MD, Wilson, Richard, MD, Pugh, Cheryl, BSc, Fisher, David, MSc, Sydes, Benjamin, Madi, Ayman, MD, Sizer, Bruce, MB, Lowdell, Charles, FRCP, Middleton, Gary, MD, Butler, Rachel, BSc, Kaplan, Richard, Prof, Maughan, Tim, Prof

“…Summary Background Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. However, how best to minimise the time…”
Get full text

Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now by MacGregor, Tom P, Maughan, Tim S, Sharma, Ricky A

“…Neoadjuvant chemoradiotherapy for locally advanced rectal cancer has been shown to decrease rates of local recurrence and more than double the rate of…”
Get more information

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer by Hurt, Christopher N., MSc, Mukherjee, Somnath, FRCP, Bridgewater, John, MD, Falk, Stephen, MD, Crosby, Tom, FRCR, McDonald, Alec, MD, Joseph, George, MBBS, Staffurth, John, MD, Abrams, Ross A., MD, Blazeby, Jane M., MD, Bridges, Sarah, BSc, Dutton, Peter, MSc, Griffiths, Gareth, PhD, Maughan, Tim, FRCR, Johnson, Colin, MChir, FRCS

“…Purpose Chemoradiation therapy (CRT) for patients with locally advanced pancreatic cancer (LAPC) provides survival benefits but may result in considerable…”
Get full text

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology by Goldberg, Richard M, Adams, Richard, Buyse, Marc, Eng, Cathy, Grothey, Axel, André, Thierry, Sobrero, Alberto F, Lichtman, Stuart M, Benson, Al B, Punt, Cornelis J A, Maughan, Tim, Burzykowski, Tomasz, Sommeijer, Dirkje, Saad, Everardo D, Shi, Qian, Coart, Elisabeth, Chibaudel, Benoist, Koopman, Miriam, Schmoll, Hans-Joachim, Yoshino, Takayuki, Taieb, Julien, Tebbutt, Niall C, Zalcberg, John, Tabernero, Josep, Van Cutsem, Eric, Matheson, Alastair, de Gramont, Aimery

“…Abstract Meta-analysis based on individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from…”
Get full text

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols by Schiavone, Francesca, Bathia, Riya, Letchemanan, Krishna, Masters, Lindsey, Amos, Claire, Bara, Anna, Brown, Louise, Gilson, Clare, Pugh, Cheryl, Atako, Nafisah, Hudson, Fleur, Parmar, Mahesh, Langley, Ruth, Kaplan, Richard S, Parker, Chris, Attard, Gert, Clarke, Noel W, Gillessen, Silke, James, Nicholas D, Maughan, Tim, Sydes, Matthew R

“…There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1)…”
Get full text

Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expansion study located at Oxford University Hospital, UK by Teoh, Suliana, Ooms, Alexander, George, Ben, Owens, Rob, Chu, Kwun-Ye, Drabble, Joe, Robinson, Maxwell, Parkes, Matthew J, Swan, Lynda, Griffiths, Lucinda, Nugent, Killian, Good, James, Maughan, Tim, Mukherjee, Somnath

“…Online adaptive MR-guided radiotherapy allows for dose escalation to pancreatic cancer while sparing surrounding critical organs. We seek to evaluate the…”
Get full text

Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons by Hague, Dominic, Townsend, Stephen, Masters, Lindsey, Rauchenberger, Mary, Van Looy, Nadine, Diaz-Montana, Carlos, Gannon, Melissa, James, Nicholas, Maughan, Tim, Parmar, Mahesh K B, Brown, Louise, Sydes, Matthew R

“…There is limited research and literature on the data management challenges encountered in multi-arm, multi-stage platform and umbrella protocols. These trial…”
Get full text

Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer by Leszczynska, Katarzyna B, Dobrynin, Greg, Leslie, Rhea E, Ient, Jonathan, Boumelha, Adam J, Senra, Joana M, Hawkins, Maria A, Maughan, Tim, Mukherjee, Somnath, Hammond, Ester M

“…Abstract Background and purpose Esophageal cancer has a persistently low 5-year survival rate and has recently been classified as a cancer of unmet need by…”
Get full text